Cancer Progress 2013 Presentations.

24th Annual Cancer Progress Conference March 5 & 6, 2013 Conrad New York

Tuesday, March 5, 2013

7:00 – 8:00am Registration and Continental Breakfast

8:15 – 8:45am Opening Remarks

8:45 – 9:15am Keynote address

9:15 – 10:15am Translational Oncology: How Far Have We Come & Where Do We Need to Go Next?

Moderator:

Panelists:

10:15 – 10:45am Networking Break

10:45 – 11:45pm Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight

Co-Moderators:

Panelists:

11:45 – 12:45pm Next Generation Diagnostic Approaches: From Arrays to Next Gen Sequencing – Will Data Points Lead Us to the Cure?

Moderator:

  • Colin Hill, Chief Executive Officer President & Chairman, GNS Healthcare

Panelists:

12:45 – 2:00pm Networking Luncheon

2:00 – 3:00pm The Challenges of Chemoprevention: How Can We Develop Drugs to Treat Cancer Risk Instead of Metastases?

Moderator:

Panelists:

3:00 – 3:30pm Networking Break

3:30 – 4:30pm Growing a Cancer-Focused Biotech: Learning from Previous and Current Business Models

Moderator:

  • Sol J. Barer, PhD, Managing Partner, SJ Barer Consulting

Panelists:

  • Michael Morrissey, PhD, President & Chief Executive Officer, Exelixis, Inc.
  • James S.J. Manuso, PhD, Chairman & Chief Executive Officer, Astex Pharmaceuticals, Inc.
  • Patrick J. Mahaffy, President & Chief Executive Officer, Clovis Oncology
  • Mark Simon, Advisor, Torreya Partners LLC

4:30- 5:30pm Cancer Metabolism: Where Exactly is the Sweet Spot?

Moderator:

Panelists:

5:30-8:30pm Cancer Progress Reception

Wednesday, March 6, 2013

7:00 – 8:00am Continental Breakfast

8:00 – 8:15am Opening Remarks

  • Mike Rice, Senior Consultant, Defined Health

8:15 – 8:45am Keynote Address

8:45 – 9:45am Cancer Stem Cells: Getting Past the Controversies – Academic and Industry Perspectives on Key Targets & Development Paths

Moderator:

Panelists:

  • George Q. Daley, MD, PhD, Samuel E. Lux IV Professor of Hematology-Oncology and Director, Stem Cell Transplantation, Program, Children’s Hospital/ Dana Farber Cancer Institute; Professor of Biological Chemistry , Harvard Medical School; Investigator, Howard Hughes Medical Institute
  • Jonathan Pachter, PhD, Vice President & Head, Research, Verastem, Inc.
  • Kenichi Nomoto, PhD, President of Eisai Oncology Unit
  • Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics, Inc.

9:45 – 10:15am Networking Break

10:15 – 11:15am Epigenetics – Are We There Yet? Building on the Foundations of DNMT and HDAC Inhibitors

Moderator:

Panelists:

11:15 – 12:15pm Pancreatic Cancer: Making the Intractable Tractable

Moderator:

  • Jordan D. Berlin, M.D. Professor of Medicine Ingram Professor of Cancer Research Clinical Director, GI Oncology Program Director, Phase I Program, Vanderbilt-Ingram Cancer Center

Panelists:

12:15 – 1:30pm Networking Luncheon

1:30 – 2:30pm Immunotherapy, Bringing It All Together: The Next Generation of Approaches & Combinations

Moderator:

Panelists:

2:30 – 3:30pm: Designing an Optimal Label for Commercial Success: When and How?

Moderator:

Panelists:

  • Chandra Ramanathan, PhD, Head Early Pipeline Oncology Global Marketing SMBU, Bayer HealthCare Pharmaceuticals
  • Usman Iqbal, MD, Senior Director and Head of Oncology, Sanofi
  • Steve Heller, Independent Consultant Situation Analysis, Strategy and Product Development

3:30 – 4:00pm: Networking Break

4:00- 5:00pm Next Generation Biologics for Cancer Therapy: Beyond the Success of Conventional Monoclonal Antibodies

Moderator:

Panelists:

  • Christian Zahnd, PhD, Chief Executive Officer, Molecular Partners AG
  • John Haurum, MD, Chief Executive Officer , F-Star
  • Hans-Peter Gerber, PhD, Executive Director, Pfizer
  • John M. Lambert, Ph.D, Executive Vice President & Chief Scientific Officer, ImmunoGen, Inc.
  • Bill Grossman MD, PhD, Senior Vice President of Research & Development, Biothera

5:00pm Closing Remarks

5:15pm Conference Concludes